Skip to content

Comparison of platelet rich plasma and estrogen-progesterone hormonal therapy in women with uterine causes of secondary amenorrhea.

Comparison of intrauterine platelet rich plasma versus oral estrogen - progesterone therapy in women with uterine causes of secondary amenorrhea: A Randomized controlled trial - NA

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111706
Enrollment
40
Registered
2026-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N911- Secondary amenorrhea

Interventions

Intervention1: Intrauterine platelet rich plasma after hysteroscopic adhesiolysis: Intrauterine platelet rich plasma will be given in women with uterine causes of secondary amenorrhea after hysterosco

Sponsors

University College of Medical Sciences and Guru Teg Bahadur Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women with complaint of Secondary amenorrhea with no withdrawal bleeding after progesterone challenge test.

Exclusion criteria

Exclusion criteria: Premature ovarian insufficiency Hyperprolactinemia Sheehan syndrome and Cushing disease Active genital TB Active PID thyroid disorder Contraindication to estrogen therapy (stroke,venous thromboembolism,coronary artery disease,active liver disease)

Design outcomes

Primary

MeasureTime frame
Restoration of menstruation in study participants after intrauterine platelet rich plasma versus oral estrogen progesterone therapy after optimal hysteroscopic adhesiolysis.Timepoint: Restoration of menstruation in study participants after intrauterine platelet rich plasma versus oral estrogen progesterone therapy after optimal hysteroscopic adhesiolysis after 1 week.

Secondary

MeasureTime frame
1. Change in endometrial thickness in both the groups from baseline. 2. Menstrual restoration after failed PRP with estrogen-progesterone therapy and vice-versa.Timepoint: 1 week after PRP or estrogen-progesterone therapy

Countries

India

Contacts

Public ContactDr Anshuja singla

University college of medical sciences and GTB hospital

ritikatetarwal@gmail.com6378743728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026